Company News: Page (1) of 1 - 04/25/14 Email this story to a friend. email article Print this page (Article printing at page facebook

Drug Development Firm and CRO Integral BioSystems LLC to Present Posters as Well as its Ophthalmic Formulation Platforms OcuSurf and EySite at ARVO 2014 in Orlando

  (April 25, 2014)
Drug Development Firm and CRO Integral BioSystems LLC to Present Posters as Well as its Ophthalmic Formulation Platforms OcuSurf and EySite at ARVO 2014 in Orlando

Boston, MA (PRWEB) April 25, 2014

Boston area ophthalmic pharmaceutical formulation developer and CRO, Integral BioSystems, will be participating the 2014 Annual Meeting of the Association for Research and Vision in Ophthalmology (ARVO), being held at the Orange County Convention Center in Orlando, Florida from May 4 7, 2014. This gathering of scientists, medical personnel, and representatives from related businesses combines a wide range of talks from commercial and academic figures in ophthalmological science, poster presentations about recent developments in ophthalmology, and offers of ophthalmology-related products and services.

OcuSurf is Integral BioSystems novel, front-of-the-eye platform designed to enhance the persistence and bioavailability of ophthalmic formulations, while EySite offers a new approach to back-of-the-eye treatments to minimize their negative effects.

Under the guidance of Dr. Barman, Integral BioSystems LLC began its operation as a pharmaceutical formulation developer and CRO in less than 200 square feet of subleased laboratory space with one employee. Less than four years later, the firm now has its own 3,500 square foot facility filled with its own state of the art equipment and 9 full-time employees.

Responsible for both the business direction and technical guidance of the firm, Dr. Barman has over 20 years of work experience in the pharmaceutical and biotech industries in areas of drug delivery, pharmaceutical development and tissue engineering. Integral BioSystems has developed numerous dosage forms for ophthalmic, oral, sublingual, intranasal, IV and transdermal routes, always taking a translational approach to drug development, customizing delivery systems to achieve the biologically effective objectives of the therapy. Dosage forms are customized to achieve sustained release or targeted, tissue-focused delivery or fast-release/instant delivery, depending upon the desired product attributes.

The Company business model is based on the following corporate objectives: (a) to be a collaborating partner in formulation development/drug product design for start-up and small companies, taking concepts from the laboratory to the clinic, (b) to re-formulate approved drugs for better efficacy and safety profiles, (c) to be a collaborating partner with API synthesis companies to develop generic drug product formats and (d) to develop its own line of proprietary pharmaceutical formulation development platform technologies for licensing by drug developers.

Read the full story at

Page: 1

Related Keywords:

Content-type: text/html  Rss  Add to Google Reader or
Homepage    Add to My AOL  Add to Excite MIX  Subscribe in
NewsGator Online 
Real-Time - what users are saying - Right Now!

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved